Opendata, web and dolomites

Fertissimo SIGNED

A ground-breaking medical system selecting the most viable embryo for successful IVF pregnancy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Fertissimo project word cloud

Explore the words cloud of the Fertissimo project. It provides you a very rough idea of what is the project "Fertissimo" about.

multiple    legacy    finances    incubated    hospitals    invasive    soon    practiced    culture    pregnancies    accommodate    manner    qualities    prospective    solid    ivf    stress    costly    met    low    facilities    profile    dependable    risk    embryos    minimise    ultimate    located    utilises    media    pregnancy    conclusive    benefit    mothers    outcomes    rapid    trial    rates    conduct    embryo    medical    procedure    foundation    quantitative    engineering    morphology    series    gold    fertissimo    leader    ivi    clinical    efficient    unprecedented    oxidative    accurate    centres    os    rate    reproductive    diagnostics    retrospective    create    excellence    2009    joins    clinics    unable    physician    forces    chances    qualify    standard    viability    single    predict    transfer    qualified    validation    biomarker    infrastructure    25    lay    equates    mass    company    global    riskier    valencia    innovation    tools    aran    certify    forming    basis    carmel    line    industrially   

Project "Fertissimo" data sheet

The following table provides information about the project.

Coordinator
CARMEL DIAGNOSTICS LTD 

Organization address
address: 9 BARLEV HAIM STREET
city: QIRYAT TIVON
postcode: 3608267
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.fertissimoivf.com
 Total cost 2˙751˙973 €
 EC max contribution 2˙711˙973 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARMEL DIAGNOSTICS LTD IL (QIRYAT TIVON) coordinator 1˙446˙486.00
2    ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD IL (CAESAEA) participant 1˙265˙487.00

Map

 Project objective

Low rates of pregnancy in IVF procedure is due to being unable to identify viable embryos for transfer. As a result, multiple embryo transfer (MET) is practiced to increase the chances of pregnancy. This is a costly procedure with riskier outcomes, which on average only equates to a 1 out of 4 rate of pregnancy success. In order to minimise the cost and risk outcomes with MET, there are increasing trends have been adopted to accommodate single embryo transfer (SET). SET however, requires more efficient embryo selection tools than current legacy morphology methods.

Fertissimo utilises a novel biomarker of oxidative stress (OS) qualities that will enable the physician’s selection of viable embryos in a rapid, non-invasive, and accurate manner. Fertissimo will provide a quantitative assessment of an embryo’s reproductive potential based on the oxidative profile of its incubated culture media. It will increase IVF pregnancy outcomes by an unprecedented 25% and beyond.

The Phase 2 project’s ultimate aim is to lay the foundation for dependable IVF pregnancies of the future. Fertissimo will set the gold standard for IVF procedure in all relevant IVF facilities, located in hospitals, medical centres, centres of IVF excellence, and clinics. Carmel Diagnostics will conduct a series of clinical validation studies, both retrospective and prospective, in order to qualify the novel OS biomarker to effectively predict embryo viability

Carmel Diagnostics (established in 2009) joins forces with Aran R&D, a leading engineering and product development company, forming a solid basis with all necessary knowledge capabilities, infrastructure and finances to support the innovation project. This would allow Carmel, and Aran, to develop, test, certify, and create the production line required for Fertissimo’s mass production.

The industrially produced Fertissimo can then be qualified in a conclusive clinical trial with Global IVF Leader IVI Valencia to the benefit of soon-to-be mothers

 Deliverables

List of deliverables.
Original Investor Relations Kit Dossier Websites, patent fillings, videos etc. 2019-03-20 11:46:21
Project website Websites, patent fillings, videos etc. 2019-03-20 11:46:21

Take a look to the deliverables list in detail:  detailed list of Fertissimo deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More